Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia
The use is described of L-carnitine and propionyl L-carnitine, or of one of their pharmaceutically acceptable salts for the preparation of a medicine for the treatment of oglioasthenoteratospermia of any origin.
1 . Use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or of their pharmaceutically acceptable salts, for the preparation of a medicine for the treatment of oligoasthenoteratospermia.
2 . Use according to claim 1 , for the preparation of a medicine for the treatment of oligospermia.
3 . Use according to claim 1 , for the preparation of a medicine for the treatment of asthenospermia.
4 . Use according to claim 1 , for the preparation of a medicine for the treatment of teratospermia.
5 . Use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine or their pharmaceutically acceptable salts, for the preparation of a nutritional composition for the treatment of oligoasthenoteratospermia.
6 . Use according to claim 5 , for the preparation of a nutritional composition for the treatment of oligospermia.
7 . Use according to claim 5 , for the preparation of a nutritional composition for the treatment of asthenospermia.
8 . Use according to claim 5 , for the preparation of a nutritional composition for the treatment of teratospermia.
9 . Use according to claim 1 in which the pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartate, acid aspartate, citrate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate, acid fumarate, magnesium fumarate, glycerophosphate, lactate, maleate and acid maleate, mucate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino ethane sulphonate, magnesium 2-amino ethane sulphonate, methane sulphonate, choline tartrate, trichloroacetate and trifluoroacetate.
10 . Use according to claim 1 , in which the L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts or their pharmaceutically acceptable salts are in a mixture or are packaged separately.
11 . Use according to claim 10 , in which the molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.098:0.092 to 0.186:0.98:0.92.
12 . Use according to claim 10 , in cui the molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.49:0.46 to 0.62:0.49:0.46.
13 . Use according to claim 10 , in which the molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.98:0.92 to 1.24:0.49:0.23.
14 . Use according to claim 11 , in which the medicine or the nutritional composition in unit dosage form contains L-carnitine inner salt in amounts ranging from 4.0 g to 0.30 g, acetyl L-carnitine inner salt in amounts ranging from 0.20 to 2.0 g, and propionyl L-carnitine inner salt in amounts ranging from 0.20 g to 2.0 g, or equimolar amounts of their pharmaceutically acceptable salts.
15 . Use according to claim 14 , in which the unit dosage form contains 2 g of L-carnitine inner salt, 1 g of acetyl L-carnitine inner salt and 0.5 g of propionyl L-carnitine inner salt or equimolar amounts of their pharmaceutically acceptable salts.